FOXP3+ regulatory T cells and their functional regulation

Cellular and Molecular Immunology

Volumn 12, Issue 5, 2015, Pages 558-565

  Li, Zhiyuan ^a   Li, Dan ^a   Tsun, Andy ^a,b   Li, Bin ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b Innovent Biologics   (China)

Author keywords

autoimmune diseases; FOXP3; immunosuppressive activity; Treg cells

Indexed keywords

CD4 ANTIGEN; CD45RA ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 35; INTERLEUKIN 7 RECEPTOR; MESSENGER RNA; NEUROPILIN 1; RAPAMYCIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR HELIOS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT1; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR;

ADOPTIVE TRANSFER; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL HETEROGENEITY; CELL THERAPY; CHEMOPROPHYLAXIS; CPG ISLAND; CRYSTAL STRUCTURE; DENDRITIC CELL; FOXP3 GENE; GRAFT VERSUS HOST REACTION; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MOLECULAR DYNAMICS; MOLECULAR STABILITY; NEOPLASM; NONHUMAN; PERIPHERALLY DERIVED REGULATORY T LYMPHOCYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASTICITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; REVIEW; THYMUS DERIVED REGULATORY T LYMPHOCYTE; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METABOLISM;

ANIMALS; CLINICAL TRIALS AS TOPIC; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; T-LYMPHOCYTES, REGULATORY;

EID: 84932642481     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2015.10     Document Type: Review

References (92)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
2. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11: 7-13.
3. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140: 845-858.
4. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP31 regulatory T cells. Nat Rev Immunol 2011; 11: 119-130.
5. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp31 regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009; 10: 689-695.
6. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD41CD251 regulatory T cells. Nat Immunol 2003; 4: 330-336.
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
8. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD41CD251 T regulatory cells. Nat Immunol 2003; 4: 337-342.
9. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68-73.
10. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20-21.
11. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK. Helios1 and Helios2 cells coexist within the natural FOXP31 T regulatory cell subset in humans. J Immunol 2013; 190: 2001-2008.
12. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp31 T regulatory cells. J Immunol 2010; 184: 3433-3441.
13. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012; 209: 1713-1722, S1-S19.
14. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T et al. Pathogenic conversion of Foxp31 T cells into TH17 cells in autoimmune arthritis. Nat Med 2014; 20: 62-68.
15. Ogawa C, Tone Y, Tsuda M, Peter C, Waldmann H, Tone M. TGF-betamediated Foxp3 gene expression is cooperatively regulated by Stat5, Creb, and AP-1 through CNS2. J Immunol 2013; 192: 475-483.
16. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010; 463: 808-812.
17. Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med 2007; 204: 1543-1551.
18. Wang L, Liu Y, Han R, Beier UH, Thomas RM, Wells AD et al. Mbd2 promotes foxp3 demethylation and T-regulatory-cell function. Mol Cell Biol 2013; 33: 4106-4115.
19. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A et al. Functional delineation and differentiation dynamics of human CD41 T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
20. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP31 regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500.
21. Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A et al. CD41 regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009; 326: 986-991.
22. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009; 10: 595-602.
23. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses. Nature 2009; 458: 351-356.
24. Yu F, Sharma S, Edwards J, FeigenbaumL, Zhu J. Dynamic expression of transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance. Nat Immunol 2015; 16: 197-206.
25. Hori S. Developmental plasticity of Foxp31 regulatory T cells. Curr Opin Immunol 2010; 22: 575-582.
26. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD41 FoxP31 T cells. Curr Opin Immunol 2009; 21: 281-285.
27. Duarte JH, Zelenay S, Bergman ML, Martins AC, Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol 2009; 39: 948-955.
28. Tsuji M, Komatsu N, Kawamoto S, Suzuki K, Kanagawa O, Honjo T et al. Preferential generation of follicularB helper T cells from Foxp31 T cells in gut Peyers patches. Science 2009; 323: 1488-1492.
29. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009; 10: 1178-1184.
30. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10: 1000-1007.
31. Chen Z, Barbi J, Bu S, Yang HY, Li Z, Gao Y et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 2013; 39: 272-285.
32. Liu X, Nguyen P, Liu W, Cheng C, Steeves M, Obenauer JC et al. T cell receptor CDR3 sequence but not recognition characteristics distinguish autoreactive effector and Foxp31 regulatory T cells. Immunity 2009; 31: 909-920.
33. Rubtsov YP, Niec RE, Josefowicz S, Li L, Darce J, Mathis D et al. Stability of the regulatory T cell lineage in vivo. Science 2010; 329: 1667-1671.
34. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp31 T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009; 106: 1903-1908.
35. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T et al. Pathogenic conversion of Foxp31 T cells into TH17 cells in autoimmune arthritis. Nat Med 2013; 20: 62-68.
36. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340-2352.
37. Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K et al. Identification of IL-17-producing FOXP31 regulatory T cells in humans. Proc Natl Acad Sci USA 2009; 106: 4793-4798.
38. Oderup C, Cederbom L, Makowska A, Cilio CM, Ivars F. Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD41 CD251 regulatory T-cellmediated suppression. Immunology 2006; 118: 240-249.
39. Serra P, Amrani A, Yamanouchi J, Han B, Thiessen S, Utsugi T et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD41CD251 T cells. Immunity 2003; 19: 877-889.
40. Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008; 180: 5916-5926.
41. Sarris M, Andersen KG, Randow F, Mayr L, Betz AG. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008; 28: 402-413.
42. Kearley J, Barker JE, Robinson DS, Lloyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer ofCD41CD251 regulatory T cells is interleukin 10 dependent. J Exp Med 2005; 202: 1539-1547.
43. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995-1004.
44. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD41CD251 regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194: 629-644.
45. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD41CD251 T regulatory cells control anti-islet CD81 T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA 2003; 100: 10878-10883.
46. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.
47. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-LHermine A, Devergne O. Human CD41 CD251 Foxp31 regulatory T cells do not constitutively express IL-35. J Immunol 2008; 181: 6898-6905.
48. Thornton AM, Shevach EM. CD41CD251 immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin2 production. J Exp Med 1998; 188: 287-296.
49. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD41CD251 regulatory T cell function. Eur J Immunol 2004; 34: 2480-2488.
50. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007; 204: 1303-1310.
51. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
52. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 59-adenosine monophosphate to adenosine. J Immunol 2006; 177: 6780-6786.
53. Li B, Samanta A, Song X, Iacono, KT, Bembas K, Tao R et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 2007; 104: 4571-4576.
54. Li Z, Lin F, Zhuo C, Deng G, Chen Z, Yin S et al. PIM1 kinase phosphorylates the human transcription factor FOXP3 at serine 422 to negatively regulate its activity under inflammation. J Biol Chem 2014; 289: 26872-26881.
55. van Loosdregt J, Fleskens V, Fu J, Brenkman AB, Bekker CP, Pals CE et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 2013; 39: 259-271.
56. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell 2011; 146: 772-784.
57. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O et al. Regulation of Treg functionality by acetylationmediated Foxp3 protein stabilization. Blood 2010; 115: 965-974.
58. Kwon HS, Lim HW, Wu J, Schnolzer M, Verdin E, Ott M. Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells. J Immunol 2012; 188: 2712-2721.
59. Morawski PA, Mehra P, Chen C, Bhatti T, Wells AD. Foxp3 protein stability is regulated by cyclin-dependent kinase 2. J Biol Chem 2013; 288: 24494-24502.
60. Nie H, Zheng Y, Li R, Guo TB, He D, Fang L et al Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNFalpha in rheumatoid arthritis. Nat Med2013; 19: 322-328.
61. Li B, Samanta A, Song X, Furuuchi K, Iacono KT, Kennedy S et al. FOXP3 ensembles in T-cell regulation. Immunol Rev 2006; 212: 99-113.
62. Li B, Samanta A, Song X, Iacono KT, Brennan P, Chatila TA et al. FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. Int Immunol 2007; 19: 825-835.
63. Song X, Li B, Xiao Y, Chen C, Wang Q, Liu Y et al. Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function. Cell Rep 2012; 1: 665-675.
64. Rudra D, deRoos P, Chaudhry A, Niec RE, Arvey A, SamsteinRMet al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol 2012; 13: 1010-1019.
65. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D et al. IL-2 regulates FOXP3 expression in human CD41CD251 regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-1579.
66. Kitoh A, Ono, M, Naoe, Y, Ohkura, N, Yamaguchi, T, Yaguchi H et al. Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP31 regulatory T cells. Immunity 2009; 31: 609-620.
67. Isomura I, Palmer S, Grumont RJ, Bunting K, Hoyne G, Wilkinson N et al. c-Rel is required for the development of thymic Foxp31 CD4 regulatory T cells. J Exp Med 2009; 206: 3001-3014.
68. Ruan, Q, Kameswaran, V, Tone, Y, Li, L, Liou, HC, Greene, MI et al. Development of Foxp31 regulatory t cells is driven by the c-Rel enhanceosome. Immunity 2009; 31: 932-940.
69. Long M, Park SG, Strickland I, Hayden MS, Ghosh S. Nuclear factorkappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 2009; 31: 921-931.
70. Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP31 conventional T cells. Eur J Immunol 2007; 37: 2378-2389.
71. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
72. Huehn J, Polansky JK, Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol 2009; 9: 83-89.
73. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T et al. Pathogenic conversion of Foxp31 T cells into TH17 cells in autoimmune arthritis. Nat Med 2006; 20: 62-68.
74. Samanta A, Li B, Song X, Bembas K, Zhang G, Katsumata M et al. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci USA 2008; 105: 14023-14027.
75. Liu Y, Wang L, Predina J, Han R, Beier UH, Wang, LC et al. Inhibition of p300 impairs Foxp31 T regulatory cell function and promotes antitumor immunity. Nat Med 2013; 19: 1173-1177.
76. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010; 138: 583-594.
77. Beier UH, Wang L, Bhatti TR, Liu Y, Han R, Ge G et al. Sirtuin-1 targeting promotes Foxp31 T-regulatory cell function and prolongs allograft survival. Mol Cell Biol 2011; 31: 1022-1029.
78. Pickart CM. Ubiquitin enters the new millennium. Mol Cell 2001; 8: 499-504.
79. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
80. Nakahira K, Morita A, Kim NS, Yanagihara I. Phosphorylation of FOXP3 by LCK downregulates MMP9 expression and represses cell invasion. PLoS One 2013; 8: e77099.
81. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
82. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.
83. Wang X, Lu L, Jiang S. Regulatory T cells: customizing for the clinic. Sci Transl Med 2011; 3: 83ps19.
84. Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, CheraiM et al. CD41CD251 regulatory T cell depletion improves the graftversus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010; 2: 41ra52.
85. Al-Homsi AS, Roy TS, Cole K, Feng Y, Duffner U. Post-transplant highdose cyclophosphamide for the prevention of graft-versus-host disease: a review. Biol Blood Marrow Transplant 2014; in press.
86. Luznik L, ODonnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012; 39: 683-693.
87. Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2014; in press.
88. Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013; 5: 211ra157.
89. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD41CD251FOXP31 regulatory T cells of both healthy subjects and type 1 diabetic patients J Immunol2006; 177: 8338-8347.
90. Wang J, Huizinga TW, Toes RE. De novo generation and enhanced suppression of humanCD41CD251 regulatory T cells by retinoic acid. J Immunol 2009; 183: 4119-4126.
91. Zhou X, Kong N, Wang J, Fan H, Zou H, Horwitz D et al. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J Immunol 2010; 185: 2675-2679.
92. Lu L, Lan Q, Li Z, Zhou X, Gu J, Li Q et al. Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc Natl Acad Sci USA 2014; 111: E3432-E3440.